GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (XPAR:ABVX) » Definitions » Other Income (Expense)

Abivax (XPAR:ABVX) Other Income (Expense) : €-7.66 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Abivax Other Income (Expense)?

Abivax's other income expense for the Abivax's pretax income for the six months ended in Dec. 2024 was €0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.66 Mil.

Abivax Other Income (Expense) Historical Data

The historical data trend for Abivax's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Other Income (Expense) Chart

Abivax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 2.42 -2.82 -7.66 1.31

Abivax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.61 2.79 -3.81 -3.84 -

Abivax Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-7.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax  (XPAR:ABVX) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Abivax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (XPAR:ABVX) » Definitions » Other Income (Expense)
Comparable Companies
XPAR:IVA XPAR:MEDCL XPAR:VLA XPAR:DBV XPAR:ALCLS XPAR:GNFT XPAR:IPH XPAR:NANO XPAR:OSE XPAR:MAAT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ABVX:USA AAVXF:USA 0RA9:UK 2X1:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.